Skip to main
MYGN
MYGN logo

Myriad Genetics (MYGN) Stock Forecast & Price Target

Myriad Genetics (MYGN) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 18%
Hold 55%
Sell 9%
Strong Sell 0%

Bulls say

Myriad Genetics Inc is poised for revenue growth, with an anticipated total revenue increase of approximately 6% year-over-year in 2026, driven predominantly by a 10% growth in its prenatal testing segment and steady mid-single-digit growth in hereditary cancer testing, tumor profiling, and pharmacogenomics, thanks to rising test volumes. The company's strategic focus on enhancing its oncology portfolio over the next 12-18 months through the launch of innovative products, such as Precise MRD and AI-enabled Prolaris, indicates a commitment to strengthening its market position. Furthermore, the upcoming debut of the RiskScore expanded panel for MyRisk and the introduction of Precise Liquid also position Myriad Genetics favorably within the evolving landscape of cancer care and diagnostics.

Bears say

Myriad Genetics Inc. is facing a negative outlook as reflected by recent downgrades to Sector Perform and a reduction in the price target to $6, indicating concerns about its financial performance and market position. The company's reliance on its molecular diagnostics offerings, while innovative, may not be fostering the robust growth needed to meet investor expectations, as suggested by the repeated downgrades. Additionally, potential challenges in competitive market dynamics and revenue generation from its diagnostic services could further impact the company's financial stability and growth trajectory.

Myriad Genetics (MYGN) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 18% recommend Buy, 55% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myriad Genetics (MYGN) Forecast

Analysts have given Myriad Genetics (MYGN) a Hold based on their latest research and market trends.

According to 11 analysts, Myriad Genetics (MYGN) has a Hold consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myriad Genetics (MYGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.